BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

267 related articles for article (PubMed ID: 24917219)

  • 1. A novel gene-protein assay for evaluating HER2 status in gastric cancer: simultaneous analyses of HER2 protein overexpression and gene amplification reveal intratumoral heterogeneity.
    Nishida Y; Kuwata T; Nitta H; Dennis E; Aizawa M; Kinoshita T; Ohtsu A; Ochiai A
    Gastric Cancer; 2015 Jul; 18(3):458-66. PubMed ID: 24917219
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparison of HER2 status between surgically resected specimens and matched biopsy specimens of gastric intestinal-type adenocarcinoma.
    Yoshida H; Yamamoto N; Taniguchi H; Oda I; Katai H; Kushima R; Tsuda H
    Virchows Arch; 2014 Aug; 465(2):145-54. PubMed ID: 24889042
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Significant intratumoral heterogeneity of human epidermal growth factor receptor 2 status in gastric cancer: A comparative study of immunohistochemistry, FISH, and dual-color in situ hybridization.
    Kanayama K; Imai H; Yoneda M; Hirokawa YS; Shiraishi T
    Cancer Sci; 2016 Apr; 107(4):536-42. PubMed ID: 26752196
    [TBL] [Abstract][Full Text] [Related]  

  • 4. HER2 intratumoral heterogeneity analyses by concurrent HER2 gene and protein assessment for the prognosis of HER2 negative invasive breast cancer patients.
    Kurozumi S; Padilla M; Kurosumi M; Matsumoto H; Inoue K; Horiguchi J; Takeyoshi I; Oyama T; Ranger-Moore J; Allred DC; Dennis E; Nitta H
    Breast Cancer Res Treat; 2016 Jul; 158(1):99-111. PubMed ID: 27318853
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Low frequency of HER2 amplification and overexpression in early onset gastric cancer.
    Moelans CB; Milne AN; Morsink FH; Offerhaus GJ; van Diest PJ
    Cell Oncol (Dordr); 2011 Apr; 34(2):89-95. PubMed ID: 21394646
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Gene protein detection platform--a comparison of a new human epidermal growth factor receptor 2 assay with conventional immunohistochemistry and fluorescence in situ hybridization platforms.
    Stålhammar G; Farrajota P; Olsson A; Silva C; Hartman J; Elmberger G
    Ann Diagn Pathol; 2015 Aug; 19(4):203-10. PubMed ID: 25921313
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comprehensive analysis of HER2 expression and gene amplification in gastric cancers using immunohistochemistry and in situ hybridization: which scoring system should we use?
    Park YS; Hwang HS; Park HJ; Ryu MH; Chang HM; Yook JH; Kim BS; Jang SJ; Kang YK
    Hum Pathol; 2012 Mar; 43(3):413-22. PubMed ID: 21855114
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A gene-protein assay for human epidermal growth factor receptor 2 (HER2): brightfield tricolor visualization of HER2 protein, the HER2 gene, and chromosome 17 centromere (CEN17) in formalin-fixed, paraffin-embedded breast cancer tissue sections.
    Nitta H; Kelly BD; Padilla M; Wick N; Brunhoeber P; Bai I; Singh S; Ranger-Moore J; Bieniarz C; Tsuda H; Grogan TM
    Diagn Pathol; 2012 May; 7():60. PubMed ID: 22647525
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Dual-colour HER2/chromosome 17 chromogenic in situ hybridisation assay enables accurate assessment of HER2 genomic status in gastric cancer and has potential utility in HER2 testing of biopsy samples.
    Yan B; Yau EX; Choo SN; Ong CW; Yong KJ; Pang B; Salto-Tellez M
    J Clin Pathol; 2011 Oct; 64(10):880-3. PubMed ID: 21757431
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparison of intratumoral heterogeneity of HER2 expression between primary tumor and multiple organ metastases in gastric cancer: Clinicopathological study of three autopsy cases and one resected case.
    Saito T; Kondo C; Shitara K; Ito Y; Saito N; Ikehara Y; Yatabe Y; Yamamichi K; Tanaka H; Nakanishi H
    Pathol Int; 2015 Jun; 65(6):309-17. PubMed ID: 25828363
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Correlation of human epidermal growth factor receptor 2 expression with clinicopathological characteristics and prognosis in gastric cancer.
    He C; Bian XY; Ni XZ; Shen DP; Shen YY; Liu H; Shen ZY; Liu Q
    World J Gastroenterol; 2013; 19(14):2171-8. PubMed ID: 23599643
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Predictive significance of HER2 intratumoral heterogeneity, determined by simultaneous gene and protein analysis, for resistance to trastuzumab-based treatments for HER2-positive breast cancer.
    Horii R; Nitta H; Nojima M; Maruyama R; Ueno T; Ito Y; Ohno S; Banks P; Kanda H; Akiyama F
    Virchows Arch; 2021 Jul; 479(1):13-21. PubMed ID: 33496805
    [TBL] [Abstract][Full Text] [Related]  

  • 13. HER2 in gastric cancer: comparative analysis of three different antibodies using whole-tissue sections and tissue microarrays.
    Abrahão-Machado LF; Jácome AA; Wohnrath DR; dos Santos JS; Carneseca EC; Fregnani JH; Scapulatempo-Neto C
    World J Gastroenterol; 2013 Oct; 19(38):6438-46. PubMed ID: 24151362
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Intratumoral heterogeneity determines discordant results of diagnostic tests for human epidermal growth factor receptor (HER) 2 in gastric cancer specimens.
    Yang J; Luo H; Li Y; Li J; Cai Z; Su X; Dai D; Du W; Chen T; Chen M
    Cell Biochem Biophys; 2012 Jan; 62(1):221-8. PubMed ID: 21927816
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Mass-spectrometry-based quantitation of Her2 in gastroesophageal tumor tissue: comparison to IHC and FISH.
    Catenacci DVT; Liao WL; Zhao L; Whitcomb E; Henderson L; O'Day E; Xu P; Thyparambil S; Krizman D; Bengali K; Uzzell J; Darfler M; Cecchi F; Blackler A; Bang YJ; Hart J; Xiao SY; Lee SM; Burrows J; Hembrough T
    Gastric Cancer; 2016 Oct; 19(4):1066-1079. PubMed ID: 26581548
    [TBL] [Abstract][Full Text] [Related]  

  • 16. HER2 Gene Protein Assay Is Useful to Determine HER2 Status and Evaluate HER2 Heterogeneity in HER2 Equivocal Breast Cancer.
    Hou Y; Nitta H; Li Z
    Am J Clin Pathol; 2017 Jan; 147(1):89-95. PubMed ID: 28110280
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Association of HER2 gene amplification and tumor progression in early gastric cancer.
    Kanayama K; Imai H; Usugi E; Shiraishi T; Hirokawa YS; Watanabe M
    Virchows Arch; 2018 Nov; 473(5):559-565. PubMed ID: 30120594
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical significance of intratumoral HER2 heterogeneity in gastric cancer.
    Lee HE; Park KU; Yoo SB; Nam SK; Park DJ; Kim HH; Lee HS
    Eur J Cancer; 2013 Apr; 49(6):1448-57. PubMed ID: 23146959
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Evaluation of HER-2/neu overexpression in gastric carcinoma using a tissue microarray.
    Rakhshani N; Kalantari E; Bakhti H; Sohrabi MR; Mehrazma M
    Asian Pac J Cancer Prev; 2014; 15(18):7597-602. PubMed ID: 25292034
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The assessment of HER2 status in breast cancer: the past, the present, and the future.
    Nitta H; Kelly BD; Allred C; Jewell S; Banks P; Dennis E; Grogan TM
    Pathol Int; 2016 Jun; 66(6):313-24. PubMed ID: 27061008
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.